June 10, 2024 Regulatory Bulletin from the Extraordinary General Meetings in InDex Pharmaceuticals Holding AB (publ) on June 10, 2024 Read more
June 7, 2024 Regulatory InDex Pharmaceuticals has received a conditional approval for continued listing on Nasdaq First North Growth Market after the reverse merger of Flerie Read more
May 27, 2024 Regulatory InDex Pharmaceuticals publishes company description in connection with the reverse merger of Flerie Read more
May 23, 2024 Regulatory Notice of extraordinary general meeting in InDex Pharmaceuticals Holding AB (publ) Read more
May 20, 2024 Regulatory InDex Pharmaceuticals has entered into a conditional agreement regarding a reverse merger with Flerie Read more
May 7, 2024 Regulatory Bulletin from the Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
May 6, 2024 Regulatory Notice of extraordinary general meeting in InDex Pharmaceuticals Holding AB (publ) Read more
April 26, 2024 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – March 2024 Read more
April 22, 2024 Regulatory InDex Pharmaceuticals brings forward the publication of the interim report for Q1 2024 Read more
April 8, 2024 Regulatory InDex Pharmaceuticals Holding AB (publ) publishes Annual Report for 2023 Read more
April 5, 2024 Regulatory Notice of Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
February 26, 2024 Regulatory InDex Pharmaceuticals discontinues the development of cobitolimod Read more
January 19, 2024 Regulatory InDex Pharmaceuticals announces expected cash balance per March 31, 2024 Read more
November 28, 2023 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January-September 2023 Read more
November 21, 2023 Regulatory InDex Pharmaceuticals discontinues cobitolimod phase III program Read more
August 23, 2023 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – June 2023 Read more
August 2, 2023 Regulatory InDex Pharmaceuticals has been granted a new patent in Europe for the commercial formulation of cobitolimod Read more
May 31, 2023 Regulatory InDex Pharmaceuticals announces license agreement with Viatris Japan to develop and commercialize cobitolimod in Japan Read more
May 24, 2023 Regulatory Bulletin from the Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
May 24, 2023 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – March 2023 Read more
April 19, 2023 Regulatory Notice of Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
April 12, 2023 Regulatory InDex Pharmaceuticals Holding AB (publ) publishes Annual Report for 2022 Read more
January 27, 2023 Regulatory InDex Pharmaceuticals updates the timeline of the phase III study CONCLUDE with cobitolimod Read more
November 23, 2022 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – September 2022 Read more
August 26, 2022 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – June 2022 Read more
July 13, 2022 Regulatory InDex Pharmaceuticals gets new patent for cobitolimod granted in Europe Read more
June 1, 2022 Regulatory Bulletin from the Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
May 16, 2022 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – March 2022 Read more
May 2, 2022 Regulatory InDex Pharmaceuticals strengthens the organization with Eva Arlander as Chief Development Officer and announces changes in the composition of the management team Read more
April 28, 2022 Regulatory Notice of Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
April 8, 2022 Regulatory InDex Pharmaceuticals Holding AB (publ) publishes Annual Report for 2021 Read more
March 13, 2022 Regulatory InDex Pharmaceuticals prepares for commercialisation of cobitolimod Read more
March 13, 2022 Regulatory InDex Pharmaceuticals prepares for commercialisation of cobitolimod Read more
February 13, 2022 Regulatory COO Pernilla Sandwall is leaving InDex Pharmaceuticals for a CEO position Read more
November 24, 2021 Regulatory InDex Pharmaceuticals enrols first patient in the phase III study CONCLUDE with cobitolimod in ulcerative colitis Read more
November 24, 2021 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – September 2021 Read more
November 16, 2021 Regulatory InDex Pharmaceuticals gets new patent for cobitolimod granted in Canada Read more
November 9, 2021 Regulatory InDex Pharmaceuticals gets new patent for cobitolimod granted in the US Read more
August 25, 2021 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – June 2021 Read more
August 24, 2021 Regulatory InDex Pharmaceuticals receives FDA clearance to start the phase III study CONCLUDE with cobitolimod Read more
July 21, 2021 Regulatory InDex Pharmaceuticals receives first regulatory approval to start the phase III study CONCLUDE with cobitolimod Read more
June 3, 2021 Regulatory Bulletin from the Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
May 31, 2021 Regulatory InDex Pharmaceuticals will initiate patient recruitment for the Phase III study CONCLUDE after the summer Read more
May 5, 2021 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – March 2021 Read more
May 4, 2021 Regulatory Notice of Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
April 23, 2021 Regulatory InDex Pharmaceuticals Holding AB (publ) publishes Annual Report for 2020 Read more
January 21, 2021 Regulatory InDex Pharmaceuticals Holding AB publishes prospectus in connection with a fully guaranteed rights issue Read more
January 14, 2021 Regulatory The board of directors of InDex Pharmaceuticals Holding AB has resolved on a fully guaranteed rights issue of approximately MSEK 533 Read more
January 12, 2021 Regulatory Bulletin from the Extraordinary General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
December 9, 2020 Regulatory Notice of Extraordinary General Meeting in InDex Pharmaceuticals Holding AB Read more
November 25, 2020 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – September 2020 Read more
November 25, 2020 Regulatory InDex Pharmaceuticals intends to carry out a fully guaranteed rights issue of approximately SEK 500 million to fund phase III development of cobitolimod Read more
August 26, 2020 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – June 2020 Read more
May 7, 2020 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – March 2020 Read more
April 20, 2020 Regulatory Bulletin from the Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
April 16, 2020 Regulatory InDex Pharmaceuticals advances cobitolimod further towards phase III following successful interactions with FDA and EMA Read more
March 30, 2020 Regulatory InDex Pharmaceuticals Holding AB (publ) publishes Annual Report for 2019 Read more
March 19, 2020 Regulatory Notice to attend the Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
February 19, 2020 Regulatory InDex Pharmaceuticals’ in-depth analysis of the CONDUCT study confirms the successful top line results and supports the strategy going forward Read more
November 27, 2019 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – September 2019 Read more
October 9, 2019 Regulatory Bulletin from Extraordinary General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
September 19, 2019 Regulatory Notice of Extraordinary General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
September 19, 2019 Regulatory InDex Pharmaceuticals has completed a directed share issue of approximately SEK 140 million (USD 14 million) Read more
September 19, 2019 Regulatory InDex Pharmaceuticals announces intention of a directed share issue Read more
August 27, 2019 Regulatory InDex Pharmaceuticals meets primary endpoint in the phase IIb study CONDUCT with cobitolimod in ulcerative colitis Read more
August 15, 2019 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – June 2019 Read more
June 26, 2019 Regulatory InDex Pharmaceuticals enrolls last patient in phase IIb study CONDUCT with cobitolimod Read more
May 6, 2019 Regulatory Bulletin from Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
May 6, 2019 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – March 2019 Read more
April 11, 2019 Regulatory InDex Pharmaceuticals provides status update on the patient recruitment in the CONDUCT study Read more
April 5, 2019 Regulatory Notice of Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
April 2, 2019 Regulatory InDex Pharmaceuticals Holding AB (publ) publishes Annual Report for 2018 Read more
November 19, 2018 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – September 2018 Read more
October 23, 2018 Regulatory InDex Pharmaceuticals carries out a directed share issue of approximately SEK 37.5 million Read more
August 28, 2018 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – June 2018 Read more
August 9, 2018 Regulatory InDex Pharmaceuticals updates timeline for top line results from the CONDUCT study to first half of 2019 Read more
May 24, 2018 Regulatory Bulletin from Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
May 17, 2018 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – March 2018 Read more
April 24, 2018 Regulatory InDex Pharmaceuticals Holding AB (publ) publishes Annual Report for 2017 Read more
April 23, 2018 Regulatory Notice of Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
December 1, 2017 Regulatory InDex Pharmaceuticals reports new mechanism of action data for cobitolimod Read more
November 17, 2017 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – September 2017 Read more
August 25, 2017 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – June 2017 Read more
June 21, 2017 Regulatory InDex Pharmaceuticals enrolls first patient in the phase IIb study CONDUCT with cobitolimod Read more
May 30, 2017 Regulatory Bulletin from Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
May 30, 2017 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – March 2017 Read more
April 27, 2017 Regulatory Notice of Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
April 27, 2017 Regulatory InDex Pharmaceuticals Holding AB (publ) publishes Annual Report for 2016 Read more
March 14, 2017 Regulatory InDex Pharmaceuticals gets patent for additional DIMS compounds granted in the US Read more
February 1, 2017 Regulatory InDex Pharmaceuticals enters agreement with CRO for the CONDUCT study Read more
November 22, 2016 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – September 2016 Read more